In today’s briefing:
- Arrail Group (6639 HK): Full-Year FY22 Results Indicate Demand Is Recovering
- Pre-IPO Rainmed Medical – The Industry, the Business and the Concerns
Arrail Group (6639 HK): Full-Year FY22 Results Indicate Demand Is Recovering
- Despite regional lockdowns caused by COVID-19 during most part of FY21, Arrail Group (6639 HK) posted 7% y/y growth in revenue, driven by 14% y/y growth in total patient visits.
- China dental services market is growing at an average 20% per annum. Arrail’s low debt and strong cash position should support its business expansion plans to grab the market opportunity.
- Despite competition, the company is expected to report accelerated double-digit revenue growth in next three years, by leveraging on its market leadership positioning and favorable macro tailwind.
Pre-IPO Rainmed Medical – The Industry, the Business and the Concerns
- The combination of FFR and IMR can provide a complete functional evaluation from epicardial arteries to myocardial microcirculation,pushing the precise diagnosis and treatment of coronary disease into a new era.
- Rainmed’s caFFR System and caIMR System have obvious technical and first-mover advantages; The CE certificate also opens up the imagination space of product commercialization (such as developing markets).
- However, the concerns on current sales model, market acceptance, medical insurance coverage, cash flow pressure and market sentiment when IPO should also not be neglected.
Before it’s here, it’s on Smartkarma